SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 39,166.00 |
| Book Value / Share | 25.26 |
| Price / Book | n/a |
| NCAV ($M) | -36,899.00 |
| NCAV / Share | -23.80 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.09 |
| Return on Assets (ROA) | 0.06 |
| Return on Equity (ROE) | 0.17 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.64 |
| Current Ratio | 0.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 25,054.00 |
| Assets | 101,119.00 |
| Liabilities | 61,953.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 45,811.00 |
| Operating Income | 8,704.00 |
| Net Income | 5,955.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 10,345.00 |
| Cash from Investing | -4,064.00 |
| Cash from Financing | -6,567.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock Inc. | 9.10 | -5.84 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 447,838 | 4,039,632 | 11.09 | |
| 510,672 | 3,633,268 | 14.06 | |
| 474,379 | 3,168,802 | 14.97 | |
| 505,330 | 1,252,097 | 40.36 | |
| 934,787 | 2,216,059 | 42.18 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ABUS – Arbutus Biopharma Corporation | ACAD – ACADIA Pharmaceuticals Inc. |
| ACLX – Arcellx, Inc. |